These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 8192436)

  • 1. New quinolones and gram-positive bacteria.
    Piddock LJ
    Antimicrob Agents Chemother; 1994 Feb; 38(2):163-9. PubMed ID: 8192436
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro activity of the new quinolones: an overview.
    Garcia-Rodriguez JA
    J Chemother; 1989 Jul; 1(4 Suppl):136-8. PubMed ID: 16312340
    [No Abstract]   [Full Text] [Related]  

  • 3. Susceptibility of non-fermentative gram-negative organisms to ureidopenicillins and quinolones.
    Moosdeen F; Tee SS; Eng CK; Yunus H
    Malays J Pathol; 1989 Aug; 11():43-7. PubMed ID: 2561170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of in vitro data with newer quinolones.
    Smith JT
    J Chemother; 1989 Jul; 1(4 Suppl):662-3. PubMed ID: 16312581
    [No Abstract]   [Full Text] [Related]  

  • 5. The antimicrobial activity of sparfloxacin, a new quinolone.
    Paradelis AG; Delidou K; Grigoriadou A; Salpigides G; Pangalis A
    Drugs; 1995; 49 Suppl 2():238-9. PubMed ID: 8549316
    [No Abstract]   [Full Text] [Related]  

  • 6. Synthesis and antibacterial activity of 7-(substituted)aminomethyl quinolones.
    Zhang Z; Zhou W; Yu A
    Bioorg Med Chem Lett; 2004 Jan; 14(2):393-5. PubMed ID: 14698166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates.
    Marshall SA; Jones RN; Murray PR; Washington JA; Allen SD; Gerlach EH; Erwin ME
    J Antimicrob Chemother; 1993 Dec; 32(6):877-84. PubMed ID: 8144428
    [No Abstract]   [Full Text] [Related]  

  • 8. Preliminary results on the antibacterial and killing activity of lomefloxacin.
    Stefani S; Pellegrino MB; Mezzatesta M; Speciale AM; Caccamo F; Russo G; Nicoletti G
    J Chemother; 1989 Jul; 1(4 Suppl):170-2. PubMed ID: 16312355
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of the antibacterial activity of lomefloxacin with that of other antibiotic/chemotherapeutic agents.
    Cuffini AM; Tullio V; Vaiani G; Carlone NA
    J Chemother; 1989 Jul; 1(4 Suppl):178-81. PubMed ID: 16312358
    [No Abstract]   [Full Text] [Related]  

  • 10. Synthesis and antibacterial activity of N-[2-(5-bromothiophen-2-yl)-2-oxoethyl] and N-[(2-5-bromothiophen-2-yl)-2-oximinoethyl] derivatives of piperazinyl quinolones.
    Foroumadi A; Emami S; Mehni M; Moshafi MH; Shafiee A
    Bioorg Med Chem Lett; 2005 Oct; 15(20):4536-9. PubMed ID: 16115766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiological profile of ozenoxacin.
    Morrissey I; Cantón R; Vila J; Gargallo-Viola D; Zsolt I; Garcia-Castillo M; López Y
    Future Microbiol; 2019 Jun; 14():773-787. PubMed ID: 31132895
    [No Abstract]   [Full Text] [Related]  

  • 12. In vitro activity of sparfloxacin against selected gram-negative blood culture isolates.
    Siristonpun Y; Rojnpisarnvong V; Chongchitmate A; Srimuang S; Tanphaichitra D
    Drugs; 1995; 49 Suppl 2():256. PubMed ID: 8549322
    [No Abstract]   [Full Text] [Related]  

  • 13. [The difluoroquinolone lomefloxacin--an broad spectrum antimicrobial drug].
    Padeĭskaia EN; Iakovlev VP
    Antibiot Khimioter; 1998; 43(2):30-9. PubMed ID: 9551171
    [No Abstract]   [Full Text] [Related]  

  • 14. In vitro selections of resistant strains by quinolones.
    López-Bartolomé O; Avial CR; Picazo JJ; Cabronero MC; Campos E
    J Chemother; 1989 Jul; 1(4 Suppl):371-3. PubMed ID: 16312445
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro assessment of the postantibiotic effect of lomefloxacin against gram-positive and gram-negative pathogens.
    Debbia EA; Pesce A; Schito GC
    Am J Med; 1992 Apr; 92(4A):45S-47S. PubMed ID: 1316070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concept, design, and preclinical evaluation of quinolonyl lactam antibacterials.
    Hershberger PM; Demuth TP
    Adv Exp Med Biol; 1998; 456():239-67. PubMed ID: 10549372
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones.
    Prats G; Roig C; Miró E; Navarro F; Mirelis B
    Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):328-34. PubMed ID: 12072950
    [No Abstract]   [Full Text] [Related]  

  • 18. High incidence of plasmid-mediated quinolone resistance (PMQR) genes among antibiotic-resistant Gram-negative bacteria from patients of the Lithuanian National Cancer Center.
    Miškinytė M; Juškaitė R; Skerniškytė J; Voldemarienė V; Valuckas KP; Kučinskienė ZA; Sužiedėlis K; Sužiedėlienė E
    Infect Dis (Lond); 2019 Jun; 51(6):471-474. PubMed ID: 30907205
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative activities of clinafloxacin against gram-positive and -negative bacteria.
    Ednie LM; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 May; 42(5):1269-73. PubMed ID: 9593165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel family (QnrAS) of plasmid-mediated quinolone resistance determinant.
    Sun HI; Jeong DU; Lee JH; Wu X; Park KS; Lee JJ; Jeong BC; Lee SH
    Int J Antimicrob Agents; 2010 Dec; 36(6):578-9. PubMed ID: 20947314
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.